应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
ABBV 艾伯维公司
休市中 04-02 16:00:00 EDT
208.84
-6.14
-2.86%
盘后
208.27
-0.57
-0.27%
19:58 EDT
最高
214.56
最低
207.71
成交量
515.11万
今开
213.99
昨收
214.98
日振幅
3.19%
总市值
3,691亿
流通市值
3,682亿
总股本
17.67亿
成交额
10.81亿
换手率
0.29%
流通股本
17.63亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
法巴银行：强生新药加入银屑病市场 艾伯维(ABBV.US)王牌药物Skyrizi面临挑战
智通财经 · 03-19
法巴银行：强生新药加入银屑病市场 艾伯维(ABBV.US)王牌药物Skyrizi面临挑战
Alloy Therapeutics与艾伯维达成多年合作协议 将获首付款及平台交付相关额外付款
美股速递 · 03-17
Alloy Therapeutics与艾伯维达成多年合作协议 将获首付款及平台交付相关额外付款
艾伯维(ABBV.US)乌帕替尼缓释片新适应症拟纳入优先审评
智通财经网 · 03-13
艾伯维(ABBV.US)乌帕替尼缓释片新适应症拟纳入优先审评
艾伯维合作伙伴Gubra宣布ABBV-295一期临床试验取得积极结果
投资观察 · 03-09
艾伯维合作伙伴Gubra宣布ABBV-295一期临床试验取得积极结果
艾伯维公布长效胰淀素类似物ABBV-295一期多剂量递增研究积极顶线结果
美股速递 · 03-09
艾伯维公布长效胰淀素类似物ABBV-295一期多剂量递增研究积极顶线结果
艾伯维高管预计2024至2029年每股收益增长将超越高个位数复合年收入增速预期
美股速递 · 03-04
艾伯维高管预计2024至2029年每股收益增长将超越高个位数复合年收入增速预期
艾伯维高管称将评估Skyrizi皮下制剂在溃疡性结肠炎诱导期的应用——TD Cowen会议
美股速递 · 03-04
艾伯维高管称将评估Skyrizi皮下制剂在溃疡性结肠炎诱导期的应用——TD Cowen会议
艾伯维公布Skyrizi®（利生奇单抗）治疗克罗恩病皮下诱导三期Affirm研究积极顶线结果
美股速递 · 03-02
艾伯维公布Skyrizi®（利生奇单抗）治疗克罗恩病皮下诱导三期Affirm研究积极顶线结果
艾伯维：Risankizumab皮下诱导疗法的安全性特征与克罗恩病已知数据一致
美股速递 · 03-02
艾伯维：Risankizumab皮下诱导疗法的安全性特征与克罗恩病已知数据一致
艾伯维公司(ABBV)拟投资3.8亿美元扩大美国生产规模
金吾财讯 · 02-24
艾伯维公司(ABBV)拟投资3.8亿美元扩大美国生产规模
艾伯维公司斥资3.8亿美元扩建北芝加哥工厂，强化美国本土原料药产能
美股速递 · 02-24
艾伯维公司斥资3.8亿美元扩建北芝加哥工厂，强化美国本土原料药产能
2025Q4| 艾伯维免疫明星表现不一：乌帕替尼强势增长，利生奇珠单抗未达预期
Minhua笔记 · 02-05
2025Q4| 艾伯维免疫明星表现不一：乌帕替尼强势增长，利生奇珠单抗未达预期
艾伯维高管预计：2026年及未来数年Skyrizi与Rinvoq将持续面临个位数低价压力
美股速递 · 02-04
艾伯维高管预计：2026年及未来数年Skyrizi与Rinvoq将持续面临个位数低价压力
艾伯维高管称公司资金充足，可同时布局早期及后期并购机遇——电话会议透露
美股速递 · 02-04
艾伯维高管称公司资金充足，可同时布局早期及后期并购机遇——电话会议透露
艾伯维高管称潜在交易不限于早期阶段，聚焦核心领域：免疫学、神经科学、肿瘤学及肥胖症布局
美股速递 · 02-04
艾伯维高管称潜在交易不限于早期阶段，聚焦核心领域：免疫学、神经科学、肿瘤学及肥胖症布局
异动解读 | 艾伯维盘中大跌7.25%，营收结构担忧、医美业务承压及一次性费用拖累股价
异动解读 · 02-04
异动解读 | 艾伯维盘中大跌7.25%，营收结构担忧、医美业务承压及一次性费用拖累股价
艾伯维高管预计：2026年Skyrizi收入将达215亿美元，Rinvoq收入将达101亿美元
美股速递 · 02-04
艾伯维高管预计：2026年Skyrizi收入将达215亿美元，Rinvoq收入将达101亿美元
异动解读 | 艾伯维盘前大跌6.5%，营收增长依赖传统药物及医美业务承压拖累股价
异动解读 · 02-04
异动解读 | 艾伯维盘前大跌6.5%，营收增长依赖传统药物及医美业务承压拖累股价
艾伯维高管预计2026年医美业务增长仍将承压 将重点投资刺激渗透率偏低市场
美股速递 · 02-04
艾伯维高管预计2026年医美业务增长仍将承压 将重点投资刺激渗透率偏低市场
医美业务复苏！艾伯维Q4财报超预期，同步上调全年利润指引
智通财经网 · 02-04
医美业务复苏！艾伯维Q4财报超预期，同步上调全年利润指引
加载更多
公司概况
公司名称：
艾伯维公司
所属市场：
NYSE
上市日期：
--
主营业务：
艾伯维公司注册成立于2012年4月10日，是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法，来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域，包括类风湿性关节炎，牛皮癣和克罗恩病，银屑病和克罗恩病;低睾酮，HIV，子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。
发行价格：
--
{"stockData":{"symbol":"ABBV","market":"US","secType":"STK","nameCN":"艾伯维公司","latestPrice":208.84,"timestamp":1775160000000,"preClose":214.98,"halted":0,"volume":5151109,"hourTrading":{"tag":"盘后","latestPrice":208.2676,"preClose":208.84,"latestTime":"19:58 EDT","volume":219806,"amount":45904190.2685,"timestamp":1775174319588,"change":-0.5724,"changeRate":-0.002741,"amplitude":0.003507},"delay":0,"changeRate":-0.02856079635314907,"floatShares":1762950764,"shares":1767384632,"eps":2.36,"marketStatus":"休市中","change":-6.14,"latestTime":"04-02 16:00:00 EDT","open":213.99,"high":214.56,"low":207.71,"amount":1080754539.86763,"amplitude":0.031863,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.36,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":214.98,"dividendRate":0.031843,"preHourTrading":{"tag":"盘前","latestPrice":215.9305,"preClose":214.98,"latestTime":"09:28 EDT","volume":2266,"amount":486448.42884,"timestamp":1775136525355,"change":0.9505,"changeRate":0.004421,"amplitude":0.023679},"postHourTrading":{"tag":"盘后","latestPrice":208.2676,"preClose":208.84,"latestTime":"19:58 EDT","volume":219806,"amount":45904190.2685,"timestamp":1775174319588,"change":-0.5724,"changeRate":-0.002741,"amplitude":0.003507},"volumeRatio":0.812130506004769,"impliedVol":0.3496,"impliedVolPercentile":0.8964},"requestUrl":"/m/hq/s/abbv","defaultTab":"news","newsList":[{"id":"2620143022","title":"法巴银行：强生新药加入银屑病市场 艾伯维(ABBV.US)王牌药物Skyrizi面临挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2620143022","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620143022?lang=zh_cn&edition=full","pubTime":"2026-03-19 14:55","pubTimestamp":1773903308,"startTime":"0","endTime":"0","summary":"智通财经APP注意到，周三，艾伯维股价下跌超5%，此前法国巴黎银行指出，其免疫学明星药物Skyrizi可能面临来自强生公司与 Protagonist Therapeutics新近获批的斑块状银屑病口服药物Icotyde的竞争。强生与 Protagonist于周三宣布，美国食品药品监督管理局已批准 Icotyde 上市。不过，泰指出，鉴于 Skyrizi 强大的疗效及其每季度一次的注射频率，艾伯维在斑块状银屑病领域仍处于有利地位。泰还提到，针对 Icotyde 在银屑病关节炎等其他炎症性疾病中的持续研究，她认为这“可能代表着对 Skyrizi 的额外竞争”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1496350171.SGD","SG9999003800.SGD","LU1496350502.SGD","LU0545039389.USD","BK4585","ABBV","LU1935042991.SGD","LU0128525929.USD","LU0122379950.USD","LU1267930573.SGD","LU2750360641.GBP","LU1934455277.USD","IE0009355771.USD","LU2471134523.USD","LU1267930813.SGD","LU0511384066.AUD","LU1066051811.HKD","BK4566","LU0058720904.USD","LU0211327993.USD","LU0289739699.SGD","IE00BVYPNW00.USD","LU0689626769.HKD","161121","BK4559","IE00BGHQF631.EUR","LU2023251221.USD","IE000M9KFDE8.USD","JNJ","LU0661504455.SGD","LU0792757196.USD","LU0320765646.SGD","LU0114720955.EUR","LU1983299246.USD","LU1074936037.SGD","LU1732799900.SGD","SG9999015986.USD","LU0057025933.USD","LU2237443895.HKD","SG9999015952.SGD","LU0795875086.SGD","LU1244550577.SGD","LU1989772923.USD","LU0345769128.USD","LU0795875169.SGD","LU1914381329.SGD","LU0158827948.USD","IE00B4R5TH58.HKD","LU1929549753.HKD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1144992166","title":"Alloy Therapeutics与艾伯维达成多年合作协议 将获首付款及平台交付相关额外付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1144992166","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144992166?lang=zh_cn&edition=full","pubTime":"2026-03-17 18:08","pubTimestamp":1773742110,"startTime":"0","endTime":"0","summary":"生物技术公司Alloy Therapeutics宣布与艾伯维公司达成一项多年期战略合作。根据协议条款，Alloy Therapeutics将获得一笔首付款，并在向艾伯维交付其专属技术平台后触发额外付款机制。此次合作将整合Alloy Therapeutics的创新平台技术与艾伯维在药物研发领域的专业优势，共同推进新型疗法的开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","IE00B3PB1722.GBP","LU1037948541.HKD","IE00B2B36J28.USD","LU0310800379.SGD","LU0820561818.USD","LU0985320562.USD","IE00BBT3K403.USD","LU1037948897.HKD","ABBV","LU1003077747.HKD","LU1244550221.USD","IE00BJJMRZ35.SGD","LU2237443622.USD","BK4588","LU0738911758.USD","LU1267930490.SGD","LU2237443382.USD","IE00BN8TJ469.HKD","LU0689626769.HKD","IE00BJT1NW94.SGD","LU1718418525.SGD","IE00B42XCP33.USD","LU0432979614.USD","LU1074936037.SGD","LU1061106388.HKD","LU2129689514.USD","LU2112291526.USD","LU2089283258.USD","LU0820561909.HKD","LU0098860793.USD","IE00BLSP4452.SGD","LU0912757837.SGD","LU0472753341.HKD","SG9999001440.SGD","LU0158827948.USD","LU1291159041.SGD","LU0965509010.AUD","IE00B4R5TH58.HKD","LU0203345920.USD","LU0882574055.USD","LU0861579265.USD","LU0545039389.USD","BK4585","LU0128525929.USD","IE00BFTCPJ56.SGD","LU0310799852.SGD","LU0417517546.SGD","LU0965508806.USD","LU0511384066.AUD","IE00BVYPNV92.GBP","LU0058720904.USD","LU0211327993.USD","LU0289739699.SGD","BK4534","LU1093756168.USD","LU0456855351.SGD","LU2129689605.HKD","LU2468319806.SGD","IE00BDGV0183.EUR","LU1057294990.SGD","IE00B19Z3B42.SGD","LU2129689431.USD","SG9999015986.USD","LU0965509101.SGD","LU1989772840.SGD","LU0965509283.SGD","LU0203347892.USD","LU1430594728.SGD","LU2237443549.SGD","LU2237443895.HKD","LU0708994859.HKD","BK4581","BK4533","IE00B19Z3581.USD","LU2347655156.SGD","LU2237443978.SGD","LU0949170772.SGD","IE00BLSP4239.USD","LU0029864427.USD","LU1267930573.SGD","LU1934455863.HKD","LU0069063385.USD","LU0289739343.SGD","LU1934455277.USD","IE0009355771.USD","LU1839511570.USD","LU1162221912.USD","LU2089284900.SGD","BK4566","LU2089984988.USD","SG9999015978.USD","LU2023251221.USD","LU0211328371.USD","LU0114720955.EUR","LU0057025933.USD","SG9999015952.SGD","IE00BSNM7G36.USD","LU1244550577.SGD","LU0289961442.SGD","LU0198837287.USD","LU1093756325.SGD","IE00BVYPNW00.USD","LU1496350171.SGD","SG9999003800.SGD","LU1496350502.SGD","LU0256863902.USD","LU0122379950.USD","LU1585245621.USD","IE0002141913.USD","LU0234572021.USD","LU0689472784.USD","LU0943347566.SGD","LU2087621335.USD","SG9999011175.SGD","BK4139","LU1934455194.USD","LU0553294199.USD","LU1551013425.SGD","LU0256863811.USD","BK4559","IE00BGHQF631.EUR","LU0661504455.SGD","IE0004445239.USD","LU1244550494.USD","SG9999015945.SGD","LU0320765646.SGD","LU1983299246.USD","LU1732799900.SGD","LU0124676726.USD","LU0234570918.USD","LU1732800096.USD","LU0795875086.SGD","LU1989772923.USD","LU0795875169.SGD","LU1023059063.AUD","LU2133065610.SGD","LU1989771016.USD","IE0002270589.USD","BK4550","LU0170899867.USD","LU1551013342.USD","LU1929549753.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619517271","title":"艾伯维(ABBV.US)乌帕替尼缓释片新适应症拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2619517271","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619517271?lang=zh_cn&edition=full","pubTime":"2026-03-13 09:23","pubTimestamp":1773365020,"startTime":"0","endTime":"0","summary":"艾伯维(ABBV.US)乌帕替尼缓释片的一项新适应症拟纳入优先审评，拟用于治疗成人和12岁及以上青少年的非节段型白癜风。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260313/20260313092241_16037.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260313/20260313092241_16037.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413409.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0124676726.USD","LU1244550494.USD","LU2089284900.SGD","IE00BSNM7G36.USD","BK4588","LU0203345920.USD","LU0689472784.USD","LU1244550221.USD","LU0965508806.USD","BK4534","LU1244550577.SGD","LU1037948897.HKD","LU0472753341.HKD","LU1496350502.SGD","LU2023251221.USD","IE00BFTCPJ56.SGD","LU0965509010.AUD","LU0057025933.USD","LU0289739343.SGD","LU2129689431.USD","LU1839511570.USD","LU0256863902.USD","LU0211328371.USD","LU0820561909.HKD","LU1430594728.SGD","LU1929549753.HKD","BK4533","LU2112291526.USD","LU1732800096.USD","LU0058720904.USD","IE00BJT1NW94.SGD","IE00BGHQF631.EUR","LU0417517546.SGD","LU1732799900.SGD","LU0289739699.SGD","LU2087621335.USD","IE00B42XCP33.USD","LU1551013342.USD","LU2237443895.HKD","ABBV","BK4566","LU1496350171.SGD","LU1989772923.USD","LU0432979614.USD","IE00BLSP4452.SGD","LU0985320562.USD","LU0029864427.USD","LU0234572021.USD","LU1162221912.USD","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130607281","title":"艾伯维合作伙伴Gubra宣布ABBV-295一期临床试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1130607281","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130607281?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:42","pubTimestamp":1773060162,"startTime":"0","endTime":"0","summary":"艾伯维公司近日公布其长效胰淀素类似物ABBV-295的一期多剂量递增试验数据，结果显示该药物表现出良好的耐受性。与安慰剂组相比，ABBV-295治疗组患者体重出现剂量依赖性显著下降，且减重幅度具备临床意义。\n此次数据为ABBV-295作为慢性体重管理差异化疗法的后续开发提供了有力支持。该药物有望为肥胖症治疗领域带来新的突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0820561818.USD","IE00BVYPNW00.USD","LU0128525929.USD","LU0943347566.SGD","LU0234570918.USD","LU2237443978.SGD","LU2237443549.SGD","IE00BJT1NW94.SGD","LU1934455863.HKD","LU2087621335.USD","IE00BLSP4239.USD","LU1585245621.USD","LU0661504455.SGD","LU1291159041.SGD","BK4588","BK4533","LU0965508806.USD","LU0689472784.USD","LU1718418525.SGD","LU1989772923.USD","SG9999015986.USD","LU0234572021.USD","LU1267930490.SGD","LU2129689605.HKD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU0472753341.HKD","LU0310800379.SGD","LU0912757837.SGD","LU1496350171.SGD","IE00B2B36J28.USD","IE00B19Z3581.USD","IE0002270589.USD","LU1003077747.HKD","LU0058720904.USD","SG9999015978.USD","IE00BSNM7G36.USD","LU0432979614.USD","IE00BGHQF631.EUR","SG9999001440.SGD","LU2237443622.USD","LU0057025933.USD","LU0965509283.SGD","LU1732800096.USD","LU1057294990.SGD","IE00B19Z3B42.SGD","LU0689626769.HKD","IE00BJJMRZ35.SGD","LU0170899867.USD","LU1929549753.HKD","LU1496350502.SGD","LU0965509101.SGD","SG9999003800.SGD","LU0289739343.SGD","LU0289961442.SGD","LU1023059063.AUD","IE00BN8TJ469.HKD","LU0124676726.USD","LU1244550221.USD","LU0114720955.EUR","LU1983299246.USD","LU2089283258.USD","LU2468319806.SGD","LU1934455277.USD","LU0098860793.USD","LU2023251221.USD","LU0211328371.USD","LU0820561909.HKD","LU1093756168.USD","LU1430594728.SGD","LU1244550577.SGD","LU1074936037.SGD","LU0456855351.SGD","LU0708994859.HKD","LU0211327993.USD","LU1989772840.SGD","LU2237443895.HKD","IE0009355771.USD","LU0882574055.USD","IE00B42XCP33.USD","LU0861579265.USD","LU1839511570.USD","LU1037948897.HKD","LU1551013342.USD","LU0738911758.USD","LU0545039389.USD","LU2347655156.SGD","LU1061106388.HKD","LU0203347892.USD","LU0256863902.USD","IE0002141913.USD","LU2133065610.SGD","LU0256863811.USD","LU2089984988.USD","LU2237443382.USD","LU1934455194.USD","LU1267930573.SGD","BK4139","IE00BDGV0183.EUR","LU0310799852.SGD","LU1551013425.SGD","ABBV","BK4566","LU0417517546.SGD","BK4550","BK4581","LU0198837287.USD","LU0795875086.SGD","IE00BVYPNV92.GBP","LU0158827948.USD","BK4585","LU0949170772.SGD","LU1093756325.SGD","LU1162221912.USD","SG9999015945.SGD","SG9999015952.SGD","LU2129689514.USD","BK4534","IE00B4R5TH58.HKD","LU1989771016.USD","LU0069063385.USD","LU2129689431.USD","LU2089284900.SGD","LU1732799900.SGD","LU0122379950.USD","LU0795875169.SGD","BK4559","LU0965509010.AUD","IE00BBT3K403.USD","LU0553294199.USD","LU0029864427.USD","LU0985320562.USD","LU1037948541.HKD","LU0203345920.USD","LU2237443465.HKD","LU1244550494.USD","LU0320765646.SGD","LU0511384066.AUD","SG9999011175.SGD","IE00BLSP4452.SGD","IE0004445239.USD","LU2112291526.USD","IE00B3PB1722.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168779828","title":"艾伯维公布长效胰淀素类似物ABBV-295一期多剂量递增研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1168779828","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168779828?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:01","pubTimestamp":1773057693,"startTime":"0","endTime":"0","summary":"艾伯维公司宣布，其长效胰淀素类似物ABBV-295在成人受试者中开展的一期多剂量递增研究获得积极顶线数据。该结果标志着该药物在临床开发阶段取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765646.SGD","LU2468319806.SGD","IE00BBT3K403.USD","IE00B2B36J28.USD","IE00BGHQF631.EUR","LU0128525929.USD","BK4139","LU2087621335.USD","LU1267930490.SGD","IE00BJJMRZ35.SGD","SG9999003800.SGD","ABBV","SG9999015952.SGD","LU0256863902.USD","LU0098860793.USD","LU2129689514.USD","LU0985320562.USD","LU1057294990.SGD","LU0058720904.USD","BK4533","LU1934455277.USD","IE00BVYPNW00.USD","LU0289961442.SGD","LU1496350171.SGD","IE0002141913.USD","LU0511384066.AUD","LU1430594728.SGD","IE0009355771.USD","BK4588","LU0417517546.SGD","LU1244550221.USD","IE00BFTCPJ56.SGD","LU0708994859.HKD","LU1093756168.USD","LU0122379950.USD","BK4534","LU1732800096.USD","BK4566","IE0002270589.USD","LU0661504455.SGD","LU1023059063.AUD","LU2237443382.USD","SG9999011175.SGD","LU0432979614.USD","LU0965509283.SGD","LU1037948541.HKD","LU2089984988.USD","LU2237443895.HKD","LU2347655156.SGD","LU0310799852.SGD","LU0689472784.USD","LU0057025933.USD","IE00B19Z3581.USD","IE00BLSP4239.USD","LU1496350502.SGD","LU0943347566.SGD","LU0795875169.SGD","SG9999015978.USD","IE00BLSP4452.SGD","IE00BVYPNV92.GBP","LU0198837287.USD","LU1244550577.SGD","BK4550","LU0820561818.USD","LU0882574055.USD","LU0965509010.AUD","LU1037948897.HKD","IE00BSNM7G36.USD","LU0211328371.USD","LU2089284900.SGD","LU0069063385.USD","LU1244550494.USD","LU0310800379.SGD","LU0289739343.SGD","LU1093756325.SGD","IE00B3PB1722.GBP","LU1074936037.SGD","LU0170899867.USD","LU0545039389.USD","LU2089283258.USD","BK4585","LU1989772840.SGD","SG9999015986.USD","LU1267930573.SGD","LU0124676726.USD","LU0234570918.USD","LU0456855351.SGD","LU1718418525.SGD","LU0029864427.USD","LU0820561909.HKD","IE0004445239.USD","LU0861579265.USD","LU1983299246.USD","IE00BJT1NW94.SGD","LU0203347892.USD","LU0738911758.USD","LU2237443465.HKD","LU0965508806.USD","LU0211327993.USD","LU0949170772.SGD","LU0689626769.HKD","LU2237443978.SGD","LU1934455194.USD","LU2129689431.USD","LU1929549753.HKD","LU1162221912.USD","LU2023251221.USD","LU1003077747.HKD","LU1732799900.SGD","IE00BN8TJ469.HKD","IE00B42XCP33.USD","LU0256863811.USD","LU1551013425.SGD","SG9999015945.SGD","BK4581","LU1989772923.USD","LU1061106388.HKD","LU1291159041.SGD","LU0203345920.USD","LU2133065610.SGD","LU1839511570.USD","LU0158827948.USD","LU1934455863.HKD","IE00B4R5TH58.HKD","LU0114720955.EUR","LU0234572021.USD","LU0472753341.HKD","LU0965509101.SGD","LU2237443622.USD","LU1989771016.USD","LU1551013342.USD","LU0553294199.USD","LU2129689605.HKD","LU0795875086.SGD","LU0289739699.SGD","IE00BDGV0183.EUR","SG9999001440.SGD","LU2237443549.SGD","IE00B19Z3B42.SGD","LU0912757837.SGD","LU1585245621.USD","LU2112291526.USD","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142685342","title":"艾伯维高管预计2024至2029年每股收益增长将超越高个位数复合年收入增速预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1142685342","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142685342?lang=zh_cn&edition=full","pubTime":"2026-03-04 00:33","pubTimestamp":1772555593,"startTime":"0","endTime":"0","summary":"艾伯维公司高管近日透露，在2024年至2029年期间，公司预计将实现超越高个位数复合年收入增长目标的每股收益扩张。这一展望凸显了企业通过运营效率提升和利润结构优化，持续推动盈利指标突破营收增长天花板的战略能力。相较于市场普遍关注的收入增长轨迹，管理层更强调每股收益的弹性增长空间，反映出其对于资本配置效率和股东回报的前瞻性布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203347892.USD","LU1291159041.SGD","LU2468319806.SGD","LU1244550221.USD","LU2237443978.SGD","LU0124676726.USD","LU1496350171.SGD","LU1989772840.SGD","LU1934455863.HKD","IE0004445239.USD","SG9999015986.USD","LU0949170772.SGD","LU2089284900.SGD","LU2237443549.SGD","LU1496350502.SGD","LU0661504455.SGD","LU1934455194.USD","IE00BLSP4239.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0472753341.HKD","LU1003077747.HKD","IE00BGHQF631.EUR","LU0289739699.SGD","LU0234570918.USD","LU0234572021.USD","LU1989771016.USD","LU1989772923.USD","LU0965509283.SGD","SG9999015945.SGD","LU1093756168.USD","LU1057294990.SGD","LU1430594728.SGD","LU1267930490.SGD","IE00B3PB1722.GBP","LU1983299246.USD","LU0820561818.USD","BK4559","LU0965509101.SGD","LU0170899867.USD","LU1732800096.USD","LU0198837287.USD","BK4566","LU0098860793.USD","LU1061106388.HKD","SG9999015978.USD","LU0820561909.HKD","LU0795875086.SGD","BK4581","LU0943347566.SGD","IE00B4R5TH58.HKD","LU0310800379.SGD","BK4585","LU0985320562.USD","LU0256863902.USD","LU1934455277.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","LU0417517546.SGD","LU1037948897.HKD","LU2089984988.USD","LU1244550577.SGD","LU0289739343.SGD","LU1732799900.SGD","LU0545039389.USD","IE00BLSP4452.SGD","LU0432979614.USD","LU2112291526.USD","IE0002270589.USD","LU0738911758.USD","LU1244550494.USD","LU2237443895.HKD","IE0009355771.USD","IE00BN8TJ469.HKD","LU0058720904.USD","LU0912757837.SGD","SG9999003800.SGD","IE00BFTCPJ56.SGD","BK4550","LU1551013425.SGD","BK4534","SG9999011175.SGD","LU2089283258.USD","IE00B42XCP33.USD","IE00BDGV0183.EUR","SG9999015952.SGD","IE00BVYPNV92.GBP","LU0965509010.AUD","IE00BVYPNW00.USD","LU1551013342.USD","BK4588","LU2237443622.USD","LU0708994859.HKD","LU1074936037.SGD","LU0256863811.USD","LU0057025933.USD","LU0211327993.USD","LU0289961442.SGD","LU0689626769.HKD","LU2087621335.USD","LU0882574055.USD","LU0029864427.USD","LU1023059063.AUD","IE0002141913.USD","IE00BSNM7G36.USD","LU2129689514.USD","BK4533","LU1718418525.SGD","LU0310799852.SGD","LU0128525929.USD","LU0456855351.SGD","LU0965508806.USD","LU1037948541.HKD","LU0511384066.AUD","IE00BBT3K403.USD","LU0114720955.EUR","LU2237443465.HKD","LU0795875169.SGD","LU1267930573.SGD","LU0320765646.SGD","LU0211328371.USD","LU1839511570.USD","BK4139","LU2347655156.SGD","IE00BJJMRZ35.SGD","LU0069063385.USD","LU1162221912.USD","LU0553294199.USD","LU2023251221.USD","LU2133065610.SGD","LU0158827948.USD","LU1093756325.SGD","LU1585245621.USD","SG9999001440.SGD","LU2129689431.USD","ABBV","LU0689472784.USD","LU1929549753.HKD","LU2237443382.USD","LU2129689605.HKD","LU0861579265.USD","LU0122379950.USD","LU0203345920.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128147669","title":"艾伯维高管称将评估Skyrizi皮下制剂在溃疡性结肠炎诱导期的应用——TD Cowen会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1128147669","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128147669?lang=zh_cn&edition=full","pubTime":"2026-03-04 00:27","pubTimestamp":1772555233,"startTime":"0","endTime":"0","summary":"艾伯维公司高管在TD Cowen会议上表示，计划对皮下注射型Skyrizi在溃疡性结肠炎诱导治疗阶段的效果展开临床评估。该举措旨在探索更便捷的给药方式对中重度患者疾病控制的潜力，若验证成功可能为患者提供传统静脉输注之外的替代方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023251221.USD","LU0795875169.SGD","LU2129689514.USD","IE00B4R5TH58.HKD","LU1732800096.USD","SG9999015986.USD","LU0158827948.USD","LU2237443978.SGD","LU1093756325.SGD","LU2112291526.USD","LU2237443382.USD","IE00BJT1NW94.SGD","LU0211328371.USD","LU0310799852.SGD","LU0708994859.HKD","LU0553294199.USD","LU0432979614.USD","LU2468319806.SGD","LU1934455194.USD","LU1934455277.USD","LU2089284900.SGD","LU1061106388.HKD","LU2129689431.USD","IE00BLSP4452.SGD","LU0069063385.USD","LU0949170772.SGD","LU0965508806.USD","IE00B19Z3581.USD","LU0965509101.SGD","IE00BLSP4239.USD","LU1037948897.HKD","ABBV","IE0002141913.USD","LU2129689605.HKD","BK4139","LU0320765646.SGD","SG9999003800.SGD","LU0057025933.USD","LU0456855351.SGD","LU0965509283.SGD","LU0122379950.USD","LU0689626769.HKD","LU1244550494.USD","SG9999001440.SGD","LU0203347892.USD","LU0124676726.USD","LU0472753341.HKD","LU2237443622.USD","LU1989771016.USD","LU1244550221.USD","IE00BVYPNV92.GBP","LU1023059063.AUD","LU1430594728.SGD","LU1291159041.SGD","LU2133065610.SGD","LU0820561909.HKD","LU1267930573.SGD","IE00BGHQF631.EUR","LU0545039389.USD","LU1732799900.SGD","IE00B2B36J28.USD","LU1074936037.SGD","LU0882574055.USD","SG9999015945.SGD","LU0203345920.USD","LU0114720955.EUR","LU0234572021.USD","IE00B19Z3B42.SGD","LU0098860793.USD","LU0985320562.USD","IE00B42XCP33.USD","IE00BDGV0183.EUR","SG9999011175.SGD","LU2347655156.SGD","LU0417517546.SGD","SG9999015978.USD","LU0795875086.SGD","LU1989772840.SGD","LU0820561818.USD","LU0256863902.USD","LU1585245621.USD","LU1551013425.SGD","LU1983299246.USD","LU1057294990.SGD","IE0002270589.USD","LU1003077747.HKD","LU1244550577.SGD","LU2237443549.SGD","BK4533","LU1496350502.SGD","LU0511384066.AUD","IE00BBT3K403.USD","LU0689472784.USD","IE00BJJMRZ35.SGD","LU0310800379.SGD","LU0234570918.USD","IE0004445239.USD","LU0211327993.USD","BK4550","IE0009355771.USD","LU0029864427.USD","LU2237443895.HKD","BK4588","LU0128525929.USD","LU1551013342.USD","LU1929549753.HKD","LU1934455863.HKD","LU2089283258.USD","BK4559","LU1989772923.USD","LU1718418525.SGD","LU0738911758.USD","LU2237443465.HKD","LU0256863811.USD","LU0170899867.USD","BK4585","LU0058720904.USD","LU0661504455.SGD","IE00B3PB1722.GBP","BK4581","LU0965509010.AUD","LU2087621335.USD","IE00BVYPNW00.USD","LU1162221912.USD","IE00BN8TJ469.HKD","LU0912757837.SGD","IE00BFTCPJ56.SGD","LU1093756168.USD","BK4534","IE00BSNM7G36.USD","LU0943347566.SGD","LU0289739699.SGD","BK4566","LU0289961442.SGD","LU0289739343.SGD","LU1037948541.HKD","LU0198837287.USD","LU1267930490.SGD","LU2089984988.USD","SG9999015952.SGD","LU1839511570.USD","LU0861579265.USD","LU1496350171.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136205999","title":"艾伯维公布Skyrizi®（利生奇单抗）治疗克罗恩病皮下诱导三期Affirm研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1136205999","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136205999?lang=zh_cn&edition=full","pubTime":"2026-03-02 21:31","pubTimestamp":1772458275,"startTime":"0","endTime":"0","summary":"艾伯维公司近日宣布，其评估Skyrizi®（利生奇单抗）皮下诱导方案用于克罗恩病患者的第三阶段Affirm研究取得了积极的顶线结果。该研究达到了其主要终点，显示出显著的治疗效果。\n这一突破性进展为克罗恩病患者提供了新的潜在治疗选择，进一步巩固了Skyrizi®在自身免疫性疾病治疗领域的地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0943347566.SGD","LU0965509283.SGD","LU1267930490.SGD","LU0289739699.SGD","LU1929549753.HKD","LU2129689514.USD","LU1732799900.SGD","LU2023251221.USD","LU0234572021.USD","LU2237443895.HKD","LU1551013425.SGD","LU1839511570.USD","LU2468319806.SGD","LU0234570918.USD","LU0256863902.USD","IE0004445239.USD","IE00BFTCPJ56.SGD","LU1551013342.USD","LU0965508806.USD","LU1934455277.USD","LU0058720904.USD","LU2237443549.SGD","LU0417517546.SGD","LU2089284900.SGD","LU1074936037.SGD","BK4139","IE00BLSP4239.USD","LU0310799852.SGD","IE00BSNM7G36.USD","IE0002141913.USD","LU1023059063.AUD","LU2089283258.USD","LU0949170772.SGD","LU1093756325.SGD","LU0289961442.SGD","LU0661504455.SGD","IE0002270589.USD","LU1496350171.SGD","LU0882574055.USD","LU2237443978.SGD","IE00B19Z3B42.SGD","BK4566","LU1244550577.SGD","LU1093756168.USD","SG9999015978.USD","LU0861579265.USD","LU1983299246.USD","LU0211327993.USD","LU0289739343.SGD","LU1732800096.USD","BK4585","IE00B42XCP33.USD","LU0820561818.USD","IE00B2B36J28.USD","IE00BLSP4452.SGD","LU0114720955.EUR","LU0122379950.USD","IE00BBT3K403.USD","IE00BN8TJ469.HKD","LU0985320562.USD","SG9999011175.SGD","LU0689472784.USD","LU0965509101.SGD","LU2087621335.USD","SG9999015986.USD","BK4588","IE00BVYPNV92.GBP","LU0795875169.SGD","IE0009355771.USD","LU2089984988.USD","BK4559","LU0456855351.SGD","LU1003077747.HKD","BK4581","LU1037948897.HKD","LU2347655156.SGD","LU0795875086.SGD","LU1037948541.HKD","LU1934455863.HKD","LU2129689431.USD","SG9999001440.SGD","LU1989771016.USD","LU2237443622.USD","LU0738911758.USD","LU0472753341.HKD","LU1585245621.USD","LU0158827948.USD","LU0545039389.USD","LU1989772840.SGD","LU1989772923.USD","LU2112291526.USD","BK4534","LU0708994859.HKD","LU0553294199.USD","LU0069063385.USD","LU0128525929.USD","LU0211328371.USD","LU0256863811.USD","IE00B3PB1722.GBP","LU0057025933.USD","SG9999003800.SGD","LU0965509010.AUD","LU0198837287.USD","LU1496350502.SGD","LU2237443465.HKD","LU0170899867.USD","ABBV","SG9999015952.SGD","LU1430594728.SGD","LU1267930573.SGD","LU0310800379.SGD","LU0124676726.USD","LU1244550221.USD","LU2129689605.HKD","IE00B4R5TH58.HKD","LU0203347892.USD","LU0320765646.SGD","IE00B19Z3581.USD","LU1061106388.HKD","IE00BDGV0183.EUR","IE00BVYPNW00.USD","LU0689626769.HKD","LU2133065610.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0203345920.USD","LU0029864427.USD","LU0820561909.HKD","SG9999015945.SGD","LU2237443382.USD","BK4550","LU1162221912.USD","LU0912757837.SGD","LU1718418525.SGD","LU1291159041.SGD","BK4533","LU0098860793.USD","LU0432979614.USD","LU1244550494.USD","LU1934455194.USD","LU0511384066.AUD","IE00BGHQF631.EUR","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107740071","title":"艾伯维：Risankizumab皮下诱导疗法的安全性特征与克罗恩病已知数据一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1107740071","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107740071?lang=zh_cn&edition=full","pubTime":"2026-03-02 21:31","pubTimestamp":1772458275,"startTime":"0","endTime":"0","summary":"艾伯维公司公布的最新研究数据显示，其药物Risankizumab在克罗恩病治疗中采用的皮下诱导方案，其安全性特征与该药物在此适应症中已知的安全性数据保持一致。这一发现进一步支持了该疗法在临床应用中的安全性表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203345920.USD","LU2133065610.SGD","LU1839511570.USD","LU0289739699.SGD","LU0472753341.HKD","LU0949170772.SGD","BK4559","LU1718418525.SGD","LU1983299246.USD","SG9999015952.SGD","LU0689626769.HKD","LU0417517546.SGD","LU1162221912.USD","LU0820561909.HKD","SG9999015986.USD","LU2129689514.USD","LU1057294990.SGD","LU2089283258.USD","LU0058720904.USD","BK4566","LU1929549753.HKD","IE00BVYPNW00.USD","LU0882574055.USD","LU0128525929.USD","BK4585","LU2347655156.SGD","LU2237443382.USD","IE00B42XCP33.USD","IE00BN8TJ469.HKD","LU0708994859.HKD","LU2087621335.USD","LU2023251221.USD","IE00BBT3K403.USD","BK4533","LU1074936037.SGD","LU0234572021.USD","LU0738911758.USD","LU0256863811.USD","LU0795875169.SGD","BK4588","LU1023059063.AUD","LU1093756325.SGD","IE00BVYPNV92.GBP","LU0689472784.USD","BK4139","LU0661504455.SGD","LU1093756168.USD","LU0965509101.SGD","LU1244550221.USD","LU0289961442.SGD","LU2468319806.SGD","LU0158827948.USD","LU1551013425.SGD","LU0198837287.USD","LU0456855351.SGD","BK4581","LU0170899867.USD","IE00B19Z3581.USD","BK4534","IE00B4R5TH58.HKD","LU0211327993.USD","LU2089984988.USD","LU2237443622.USD","IE0002270589.USD","LU1003077747.HKD","LU0069063385.USD","LU1244550494.USD","LU0114720955.EUR","LU0432979614.USD","IE00BJJMRZ35.SGD","LU1496350171.SGD","LU0912757837.SGD","LU0122379950.USD","LU1732799900.SGD","SG9999001440.SGD","SG9999003800.SGD","LU1989772923.USD","IE00BJT1NW94.SGD","IE00B3PB1722.GBP","LU0310800379.SGD","LU1430594728.SGD","LU0203347892.USD","LU2237443465.HKD","LU1989772840.SGD","IE00BSNM7G36.USD","LU0553294199.USD","LU0965509010.AUD","LU1934455863.HKD","IE00B2B36J28.USD","BK4550","LU2129689431.USD","IE0004445239.USD","LU0965508806.USD","SG9999011175.SGD","LU1267930490.SGD","LU1934455277.USD","LU0289739343.SGD","LU0985320562.USD","LU0861579265.USD","IE00BGHQF631.EUR","LU0124676726.USD","LU0943347566.SGD","LU0057025933.USD","IE00B19Z3B42.SGD","LU1496350502.SGD","LU0211328371.USD","LU0795875086.SGD","LU0098860793.USD","LU2129689605.HKD","LU1037948897.HKD","LU0511384066.AUD","LU0234570918.USD","LU1037948541.HKD","LU0310799852.SGD","LU2237443978.SGD","LU0965509283.SGD","LU0545039389.USD","LU0820561818.USD","ABBV","LU1585245621.USD","IE00BFTCPJ56.SGD","IE00BLSP4239.USD","LU1989771016.USD","LU1934455194.USD","LU2237443895.HKD","LU2089284900.SGD","IE00BLSP4452.SGD","LU0256863902.USD","LU2237443549.SGD","LU1291159041.SGD","LU1267930573.SGD","LU0320765646.SGD","SG9999015945.SGD","LU1732800096.USD","IE0009355771.USD","IE0002141913.USD","LU1551013342.USD","SG9999015978.USD","LU1061106388.HKD","LU0029864427.USD","LU2112291526.USD","LU1244550577.SGD","IE00BDGV0183.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613792389","title":"艾伯维公司(ABBV)拟投资3.8亿美元扩大美国生产规模","url":"https://stock-news.laohu8.com/highlight/detail?id=2613792389","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613792389?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:08","pubTimestamp":1771927700,"startTime":"0","endTime":"0","summary":"金吾财讯 | 艾伯维表示，将投资3.8亿美元在美国伊利诺伊州园区建造两座新的活性药物成分生产设施，以扩大其神经科学和减肥药物的国内生产能力。 公司在美国已经拥有11个生产基地，并且正在与美国多个州就潜在项目进行磋商，预计将于今年宣布进一步投资。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"297436","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","IE00BJJMRZ35.SGD","BK4550","LU1093756168.USD","SG9999015978.USD","LU0158827948.USD","IE0002141913.USD","LU1057294990.SGD","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","LU1244550494.USD","LU1989771016.USD","LU2089984988.USD","LU1732800096.USD","IE00BN8TJ469.HKD","LU1496350502.SGD","SG9999011175.SGD","LU2129689431.USD","LU0256863902.USD","LU0965509283.SGD","LU1839511570.USD","LU2023251221.USD","LU0689626769.HKD","LU1291159041.SGD","LU0114720955.EUR","LU1244550221.USD","LU0661504455.SGD","LU0965509101.SGD","LU2129689514.USD","IE00B4R5TH58.HKD","IE00B42XCP33.USD","BK4139","LU0310800379.SGD","LU2237443465.HKD","LU2129689605.HKD","LU0738911758.USD","IE00BJT1NW94.SGD","IE00BBT3K403.USD","LU0545039389.USD","LU1551013342.USD","LU2089283258.USD","LU0057025933.USD","LU0949170772.SGD","LU0058720904.USD","LU1003077747.HKD","IE00B3PB1722.GBP","LU0965509010.AUD","LU0211328371.USD","ABBV","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153031519","title":"艾伯维公司斥资3.8亿美元扩建北芝加哥工厂，强化美国本土原料药产能","url":"https://stock-news.laohu8.com/highlight/detail?id=1153031519","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153031519?lang=zh_cn&edition=full","pubTime":"2026-02-24 00:00","pubTimestamp":1771862412,"startTime":"0","endTime":"0","summary":"艾伯维公司宣布一项重大投资计划，将投入3.8亿美元用于其位于北芝加哥的生产基地。此项投资旨在显著提升其在美国境内的活性药物成分（API）的制造能力，进一步巩固其本土供应链。\n通过扩建现有设施，艾伯维致力于加强关键药物的生产保障，确保稳定供应。这一战略举措不仅体现了公司对创新制药的持续承诺，也凸显了其强化美国本土制造业布局的决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128525929.USD","LU0058720904.USD","BK4534","LU0122379950.USD","BK4566","LU0098860793.USD","LU0310800379.SGD","LU0456855351.SGD","LU2023251221.USD","SG9999015986.USD","LU2347655156.SGD","LU2129689514.USD","LU0114720955.EUR","IE00B4R5TH58.HKD","IE00B3PB1722.GBP","LU1093756325.SGD","LU0708994859.HKD","IE00B2B36J28.USD","LU1061106388.HKD","IE00BLSP4452.SGD","LU0234570918.USD","IE00BFTCPJ56.SGD","LU1037948541.HKD","LU2129689431.USD","LU0170899867.USD","LU0203345920.USD","LU2129689605.HKD","LU1585245621.USD","LU1244550494.USD","LU0234572021.USD","LU0689626769.HKD","LU0256863902.USD","LU2089283258.USD","LU0965509283.SGD","SG9999011175.SGD","ABBV","IE00BVYPNV92.GBP","LU0545039389.USD","LU1496350502.SGD","LU0310799852.SGD","LU0211327993.USD","LU1929549753.HKD","LU1989771016.USD","IE0009355771.USD","LU2237443382.USD","LU0985320562.USD","LU0198837287.USD","LU1244550221.USD","LU0795875169.SGD","LU0124676726.USD","LU2089284900.SGD","IE00B42XCP33.USD","LU2112291526.USD","LU0553294199.USD","LU2087621335.USD","IE00BJT1NW94.SGD","LU1934455277.USD","LU2237443895.HKD","LU0882574055.USD","LU0738911758.USD","LU0820561909.HKD","LU0029864427.USD","LU1093756168.USD","BK4588","LU1430594728.SGD","LU1267930490.SGD","LU1003077747.HKD","LU1839511570.USD","LU0256863811.USD","IE00BBT3K403.USD","LU0289739343.SGD","BK4533","LU1732800096.USD","SG9999003800.SGD","LU0965509101.SGD","LU1037948897.HKD","LU2237443465.HKD","IE0002270589.USD","LU2237443978.SGD","LU0795875086.SGD","LU0943347566.SGD","LU1057294990.SGD","LU0057025933.USD","IE00BDGV0183.EUR","LU2237443622.USD","LU0432979614.USD","LU0320765646.SGD","IE00B19Z3B42.SGD","LU1934455863.HKD","LU0069063385.USD","LU1162221912.USD","LU1291159041.SGD","LU1989772840.SGD","IE0004445239.USD","LU1023059063.AUD","BK4581","LU2133065610.SGD","LU0820561818.USD","LU0965509010.AUD","IE00BSNM7G36.USD","LU0511384066.AUD","IE00BGHQF631.EUR","LU0689472784.USD","SG9999015945.SGD","BK4550","LU0965508806.USD","IE00BN8TJ469.HKD","LU1983299246.USD","LU0472753341.HKD","LU1074936037.SGD","LU0861579265.USD","LU1989772923.USD","LU0158827948.USD","IE0002141913.USD","IE00BLSP4239.USD","SG9999001440.SGD","SG9999015978.USD","LU1244550577.SGD","LU0949170772.SGD","LU0912757837.SGD","LU1551013425.SGD","BK4559","LU1551013342.USD","LU2468319806.SGD","LU1267930573.SGD","LU0289739699.SGD","LU0211328371.USD","LU2237443549.SGD","IE00B19Z3581.USD","LU0661504455.SGD","LU1934455194.USD","LU1732799900.SGD","IE00BJJMRZ35.SGD","LU2089984988.USD","LU0417517546.SGD","LU0289961442.SGD","LU1496350171.SGD","BK4585","BK4139","SG9999015952.SGD","LU0203347892.USD","IE00BVYPNW00.USD","LU1718418525.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609558780","title":"2025Q4| 艾伯维免疫明星表现不一：乌帕替尼强势增长，利生奇珠单抗未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2609558780","media":"Minhua笔记","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609558780?lang=zh_cn&edition=full","pubTime":"2026-02-05 13:57","pubTimestamp":1770271040,"startTime":"0","endTime":"0","summary":"2月4日，艾伯维公布2025年第四季度及全年业绩，营收和盈利均超预期。公司股价当天下跌约4%，投资者对Humira衰退期公司增长仍依赖该药表示担忧。艾伯维第四季度销售额超出预期约2亿美元，这主要得益于其重磅药物Humira的出色表现，而其后续免疫学药物Rinvoq强势增长，但Skyrizi的业绩则低于预期。Skyrizi 增长 32.5%，达到 50 亿美元，超过预期的 49 亿美元；Rinvoq 增长 29.5%，达到 23.7 亿美元，但略低于预期。其中，Skyrizi和Rinvoq预计分别贡献约215亿美元和101亿美元的收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205152126a47f0cd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205152126a47f0cd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z3B42.SGD","LU2129689514.USD","ABBV","BK4559","LU2129689605.HKD","LU1718418525.SGD","LU0320765646.SGD","LU0256863811.USD","SG9999003800.SGD","LU0158827948.USD","LU2347655156.SGD","LU2237443978.SGD","LU0965509283.SGD","BK4585","SG9999015978.USD","SG9999001440.SGD","LU0820561818.USD","LU0256863902.USD","LU1585245621.USD","IE00B3PB1722.GBP","LU2112291526.USD","LU0124676726.USD","LU2237443622.USD","LU1989771016.USD","IE0002270589.USD","LU2468319806.SGD","LU2237443549.SGD","LU1430594728.SGD","LU0912757837.SGD","LU0511384066.AUD","IE00BFTCPJ56.SGD","IE00BBT3K403.USD","LU1267930573.SGD","IE00BGHQF631.EUR","IE00BJJMRZ35.SGD","LU0310800379.SGD","IE00BSNM7G36.USD","IE0004445239.USD","LU0211327993.USD","BK4566","LU0289961442.SGD","LU0289739343.SGD","LU2237443895.HKD","LU1551013342.USD","LU1037948541.HKD","LU1929549753.HKD","SG9999015952.SGD","LU2089283258.USD","LU0861579265.USD","LU0203345920.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152082663","title":"艾伯维高管预计：2026年及未来数年Skyrizi与Rinvoq将持续面临个位数低价压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1152082663","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152082663?lang=zh_cn&edition=full","pubTime":"2026-02-04 23:32","pubTimestamp":1770219134,"startTime":"0","endTime":"0","summary":"艾伯维公司高管近日表示，旗下明星药物Skyrizi（瑞莎珠单抗）与Rinvoq（乌帕替尼）在2026年及后续几年中，预计将持续承受较低的个位数百分比定价阻力。这一预测反映出生物制药行业在医保控费与市场竞争双重压力下的新常态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1291159041.SGD","LU0432979614.USD","LU2237443549.SGD","IE00B3PB1722.GBP","LU1430594728.SGD","LU2237443622.USD","LU1718418525.SGD","LU2237443465.HKD","LU2237443895.HKD","BK4566","LU0689472784.USD","SG9999001440.SGD","LU1934455863.HKD","LU0965509101.SGD","IE00BJT1NW94.SGD","LU1074936037.SGD","LU0545039389.USD","LU1037948541.HKD","LU1023059063.AUD","LU2089984988.USD","LU1989772923.USD","LU1093756325.SGD","LU0069063385.USD","LU0795875086.SGD","LU0128525929.USD","LU0689626769.HKD","LU0965509283.SGD","LU0114720955.EUR","LU1732799900.SGD","SG9999015952.SGD","LU1496350171.SGD","IE00BLSP4239.USD","LU2112291526.USD","LU0965508806.USD","IE00B4R5TH58.HKD","LU0289961442.SGD","LU0943347566.SGD","LU0320765646.SGD","LU2347655156.SGD","LU0310800379.SGD","LU1983299246.USD","SG9999011175.SGD","LU1989771016.USD","LU0029864427.USD","LU0057025933.USD","LU0170899867.USD","IE0009355771.USD","LU0234570918.USD","BK4533","IE00BDGV0183.EUR","ABBV","LU2129689514.USD","LU1244550577.SGD","LU2468319806.SGD","LU0985320562.USD","IE00BVYPNW00.USD","LU0708994859.HKD","IE00BGHQF631.EUR","SG9999003800.SGD","LU0511384066.AUD","LU1061106388.HKD","LU1162221912.USD","LU1244550494.USD","BK4588","LU2129689431.USD","LU0256863811.USD","LU0098860793.USD","LU0203345920.USD","LU1934455194.USD","LU1551013425.SGD","LU0912757837.SGD","LU0289739343.SGD","LU2023251221.USD","LU0203347892.USD","LU1934455277.USD","LU0472753341.HKD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0661504455.SGD","LU1551013342.USD","LU0738911758.USD","LU0234572021.USD","LU0211328371.USD","LU0211327993.USD","LU1037948897.HKD","SG9999015986.USD","LU0417517546.SGD","LU0456855351.SGD","LU2133065610.SGD","IE00B19Z3581.USD","LU0124676726.USD","BK4559","BK4585","LU1093756168.USD","LU0310799852.SGD","LU0795875169.SGD","IE00BLSP4452.SGD","LU0553294199.USD","LU1003077747.HKD","LU1989772840.SGD","LU1732800096.USD","LU0256863902.USD","LU0820561909.HKD","LU0058720904.USD","BK4581","IE00BBT3K403.USD","LU1496350502.SGD","LU0861579265.USD","LU1057294990.SGD","LU2237443382.USD","LU0198837287.USD","LU1267930573.SGD","LU1585245621.USD","IE0002270589.USD","LU2087621335.USD","IE00B42XCP33.USD","IE00BVYPNV92.GBP","LU1267930490.SGD","BK4550","IE00BN8TJ469.HKD","LU2129689605.HKD","LU0122379950.USD","LU2237443978.SGD","LU2089283258.USD","LU0158827948.USD","LU0965509010.AUD","LU0289739699.SGD","LU0882574055.USD","LU0820561818.USD","IE0004445239.USD","SG9999015945.SGD","IE00BSNM7G36.USD","LU2089284900.SGD","LU1839511570.USD","BK4534","IE0002141913.USD","IE00B19Z3B42.SGD","LU1244550221.USD","SG9999015978.USD","IE00BFTCPJ56.SGD","LU1929549753.HKD","LU0949170772.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128110797","title":"艾伯维高管称公司资金充足，可同时布局早期及后期并购机遇——电话会议透露","url":"https://stock-news.laohu8.com/highlight/detail?id=1128110797","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128110797?lang=zh_cn&edition=full","pubTime":"2026-02-04 23:31","pubTimestamp":1770219079,"startTime":"0","endTime":"0","summary":"艾伯维公司高管在最新电话会议中表示，公司目前拥有充足的资金实力，能够同步推进早期阶段与成熟阶段的并购机会。这一表态凸显了艾伯维在生物医药领域持续扩张的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089284900.SGD","LU0310799852.SGD","LU0820561909.HKD","LU0795875086.SGD","LU1074936037.SGD","LU0943347566.SGD","LU1585245621.USD","LU0310800379.SGD","IE00BSNM7G36.USD","LU1037948541.HKD","SG9999015945.SGD","LU0203345920.USD","LU1093756325.SGD","IE0002270589.USD","LU2023251221.USD","LU0432979614.USD","LU0211327993.USD","LU2129689431.USD","LU2129689514.USD","LU0320765646.SGD","BK4550","LU0820561818.USD","LU0128525929.USD","LU2347655156.SGD","LU1989771016.USD","IE00BLSP4452.SGD","LU0058720904.USD","LU1244550221.USD","LU1093756168.USD","LU0211328371.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU2237443895.HKD","LU2089283258.USD","LU1057294990.SGD","LU1267930490.SGD","LU1496350171.SGD","LU1989772840.SGD","LU0965509010.AUD","LU1551013342.USD","SG9999003800.SGD","LU0965509283.SGD","LU1430594728.SGD","LU0057025933.USD","LU2112291526.USD","IE00BJJMRZ35.SGD","BK4588","LU1934455277.USD","LU0882574055.USD","LU1732799900.SGD","BK4139","IE00BN8TJ469.HKD","SG9999015986.USD","LU1934455194.USD","LU1983299246.USD","LU1003077747.HKD","LU0708994859.HKD","LU1718418525.SGD","BK4559","LU0098860793.USD","LU0122379950.USD","BK4581","LU0203347892.USD","LU1037948897.HKD","LU0985320562.USD","LU0949170772.SGD","IE0004445239.USD","LU0511384066.AUD","LU0965509101.SGD","LU0289961442.SGD","LU0069063385.USD","LU1291159041.SGD","LU0795875169.SGD","LU0738911758.USD","LU2237443382.USD","BK4566","LU0289739343.SGD","IE00BGHQF631.EUR","LU0124676726.USD","LU1934455863.HKD","LU1989772923.USD","LU1244550494.USD","LU0256863902.USD","IE00B19Z3B42.SGD","LU1551013425.SGD","LU2237443549.SGD","LU0289739699.SGD","BK4585","IE00B3PB1722.GBP","LU0912757837.SGD","LU2237443978.SGD","LU0170899867.USD","LU0417517546.SGD","IE00B19Z3581.USD","LU0029864427.USD","LU0158827948.USD","LU0234570918.USD","IE0009355771.USD","LU0545039389.USD","LU2237443465.HKD","ABBV","LU0198837287.USD","LU0861579265.USD","LU2089984988.USD","IE00BBT3K403.USD","LU0472753341.HKD","LU2237443622.USD","LU1061106388.HKD","LU2087621335.USD","LU1732800096.USD","IE00B4R5TH58.HKD","LU1162221912.USD","IE00BVYPNW00.USD","LU2133065610.SGD","LU2129689605.HKD","LU0256863811.USD","IE00BVYPNV92.GBP","LU0114720955.EUR","LU0553294199.USD","IE00BJT1NW94.SGD","LU1929549753.HKD","SG9999015952.SGD","IE0002141913.USD","LU0661504455.SGD","SG9999015978.USD","LU1244550577.SGD","IE00BDGV0183.EUR","LU2468319806.SGD","LU1023059063.AUD","LU1839511570.USD","BK4533","LU0965508806.USD","LU0689472784.USD","BK4534","SG9999001440.SGD","LU0234572021.USD","IE00BLSP4239.USD","LU0689626769.HKD","LU1267930573.SGD","IE00B42XCP33.USD","LU1496350502.SGD","LU0456855351.SGD","SG9999011175.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138286335","title":"艾伯维高管称潜在交易不限于早期阶段，聚焦核心领域：免疫学、神经科学、肿瘤学及肥胖症布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1138286335","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138286335?lang=zh_cn&edition=full","pubTime":"2026-02-04 23:30","pubTimestamp":1770219013,"startTime":"0","endTime":"0","summary":"艾伯维公司高管近日表示，公司在寻求潜在交易时不会局限于早期阶段项目，而是将战略重点集中于核心业务领域。这些关键领域包括免疫学、神经科学、肿瘤学，以及正在积极拓展的肥胖症治疗方向。公司旨在通过多元化的合作方式强化产品管线，推动长期增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875169.SGD","BK4139","LU1496350171.SGD","LU2468319806.SGD","LU0472753341.HKD","LU0689626769.HKD","LU0158827948.USD","IE00BN8TJ469.HKD","LU0289739699.SGD","LU1037948541.HKD","LU0795875086.SGD","LU2347655156.SGD","IE00BLSP4239.USD","IE00B3PB1722.GBP","SG9999015952.SGD","LU1934455863.HKD","LU0417517546.SGD","LU0234572021.USD","LU0432979614.USD","LU0289961442.SGD","LU2129689514.USD","LU1093756168.USD","LU0122379950.USD","LU0114720955.EUR","LU2133065610.SGD","BK4533","LU1929549753.HKD","SG9999015978.USD","LU0029864427.USD","LU0965508806.USD","LU2087621335.USD","SG9999015986.USD","LU0203347892.USD","LU0058720904.USD","LU0661504455.SGD","BK4550","LU2237443465.HKD","ABBV","LU0310799852.SGD","LU0320765646.SGD","LU1989772923.USD","LU1093756325.SGD","LU1267930490.SGD","LU2237443622.USD","LU2129689431.USD","LU0553294199.USD","LU1267930573.SGD","LU1496350502.SGD","SG9999001440.SGD","LU2089984988.USD","LU2089284900.SGD","SG9999015945.SGD","LU0256863902.USD","LU0985320562.USD","LU0820561818.USD","LU0124676726.USD","IE00B19Z3581.USD","BK4585","IE00BVYPNV92.GBP","LU1057294990.SGD","IE00B4R5TH58.HKD","LU0128525929.USD","LU1934455194.USD","LU0211328371.USD","IE0002270589.USD","IE00BLSP4452.SGD","LU1074936037.SGD","LU0949170772.SGD","LU0203345920.USD","IE00BJT1NW94.SGD","BK4534","LU0289739343.SGD","IE00B19Z3B42.SGD","LU1244550577.SGD","LU1162221912.USD","LU0069063385.USD","LU1291159041.SGD","LU0456855351.SGD","LU1551013425.SGD","IE00BJJMRZ35.SGD","IE00B42XCP33.USD","IE00BDGV0183.EUR","LU1989771016.USD","LU0943347566.SGD","LU0511384066.AUD","LU0820561909.HKD","LU1989772840.SGD","LU1061106388.HKD","LU0545039389.USD","LU1037948897.HKD","IE0002141913.USD","LU1244550221.USD","IE00BVYPNW00.USD","LU0965509010.AUD","LU1551013342.USD","LU2023251221.USD","LU1934455277.USD","LU2089283258.USD","LU0882574055.USD","LU1983299246.USD","LU1244550494.USD","LU0057025933.USD","LU1718418525.SGD","LU2129689605.HKD","LU0098860793.USD","LU1732800096.USD","LU0738911758.USD","BK4566","BK4588","IE0004445239.USD","LU0310800379.SGD","LU0198837287.USD","LU2112291526.USD","IE00B2B36J28.USD","SG9999011175.SGD","LU2237443895.HKD","SG9999003800.SGD","IE00BBT3K403.USD","LU0912757837.SGD","IE00BSNM7G36.USD","LU1585245621.USD","LU1003077747.HKD","LU0170899867.USD","LU1430594728.SGD","IE0009355771.USD","LU0965509101.SGD","LU0861579265.USD","LU0211327993.USD","LU1023059063.AUD","LU1732799900.SGD","BK4559","LU2237443382.USD","LU2237443549.SGD","LU2237443978.SGD","LU0708994859.HKD","IE00BFTCPJ56.SGD","LU0689472784.USD","IE00BGHQF631.EUR","LU0234570918.USD","LU1839511570.USD","LU0965509283.SGD","LU0256863811.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186940641","title":"异动解读 | 艾伯维盘中大跌7.25%，营收结构担忧、医美业务承压及一次性费用拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1186940641","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186940641?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:41","pubTimestamp":1770216062,"startTime":"0","endTime":"0","summary":"艾伯维（ABBV）今日盘中股价大幅下跌7.25%，引发了市场广泛关注。消息面上，尽管公司预测2026年利润高于预期，但分析师指出其营收增长主要依赖传统药物Humira，而该药销售额正受到仿制药侵蚀，引发了市场对营收结构可持续性的担忧。同时，公司高管预计2026年医美业务增长仍将面临挑战，需通过投资刺激渗透率偏低的市场。此外，公司最新公布的第四季度业绩受到收购相关无形资产研发及里程碑费用的显著拖累，这些一次性支出对每股收益造成了0.71美元的负面影响。市场对上述因素的叠加反应，共同导致了此次股价的大幅下挫。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABBV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135576917","title":"艾伯维高管预计：2026年Skyrizi收入将达215亿美元，Rinvoq收入将达101亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135576917","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135576917?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:36","pubTimestamp":1770215794,"startTime":"0","endTime":"0","summary":"艾伯维公司高管近日透露，预计到2026年，其明星产品Skyrizi的年收入将攀升至215亿美元，而同为重磅药物的Rinvoq也将实现101亿美元的营收目标。这一预测凸显了公司对这两款免疫疾病治疗药物市场前景的强烈信心。\n随着全球自身免疫疾病患者群体的持续扩大，Skyrizi和Rinvoq凭借卓越的临床疗效，正逐步成为细分领域的领军产品。分析指出，若能达到预期目标，这两款药物将共同构筑艾伯维未来业绩增长的双引擎，有效抵消明星修美乐专利到期后带来的收入压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087621335.USD","LU1037948897.HKD","LU0432979614.USD","SG9999015986.USD","LU0472753341.HKD","LU1732799900.SGD","LU0170899867.USD","LU2237443895.HKD","ABBV","LU1732800096.USD","LU1934455194.USD","LU0795875169.SGD","LU1929549753.HKD","LU2237443549.SGD","LU0456855351.SGD","LU0198837287.USD","IE00BVYPNW00.USD","LU1267930490.SGD","LU2129689431.USD","LU0949170772.SGD","LU1244550494.USD","LU0256863902.USD","IE0002141913.USD","LU0965509283.SGD","LU1989772840.SGD","IE00BBT3K403.USD","LU0661504455.SGD","LU1551013425.SGD","LU1162221912.USD","BK4139","LU1983299246.USD","LU0820561818.USD","LU0158827948.USD","LU1074936037.SGD","LU1585245621.USD","LU0310800379.SGD","LU0795875086.SGD","SG9999015978.USD","IE00BGHQF631.EUR","LU0057025933.USD","LU1430594728.SGD","LU0203347892.USD","LU1003077747.HKD","LU1093756325.SGD","LU0545039389.USD","LU0122379950.USD","BK4550","LU0128525929.USD","LU0708994859.HKD","LU0234570918.USD","LU0310799852.SGD","LU1989772923.USD","SG9999001440.SGD","LU1267930573.SGD","IE00BFTCPJ56.SGD","LU0289961442.SGD","IE00B19Z3581.USD","LU1023059063.AUD","LU0256863811.USD","IE0002270589.USD","IE0004445239.USD","IE00BLSP4239.USD","IE00BDGV0183.EUR","LU0029864427.USD","LU1291159041.SGD","LU0203345920.USD","LU2089984988.USD","LU2237443465.HKD","LU2347655156.SGD","LU2023251221.USD","LU2237443978.SGD","LU1934455277.USD","BK4581","BK4534","LU2089284900.SGD","LU0417517546.SGD","LU0553294199.USD","LU0882574055.USD","LU0965508806.USD","SG9999015945.SGD","SG9999003800.SGD","BK4533","LU0098860793.USD","BK4588","IE00BVYPNV92.GBP","LU2237443622.USD","IE00B42XCP33.USD","IE00B4R5TH58.HKD","LU0820561909.HKD","BK4566","LU1496350171.SGD","LU0124676726.USD","LU0965509010.AUD","LU2468319806.SGD","IE00B2B36J28.USD","LU1057294990.SGD","LU1093756168.USD","IE00BJJMRZ35.SGD","LU0211327993.USD","LU0943347566.SGD","BK4585","LU1061106388.HKD","LU1934455863.HKD","LU0985320562.USD","IE00B3PB1722.GBP","LU0912757837.SGD","SG9999015952.SGD","LU0234572021.USD","LU0511384066.AUD","LU1718418525.SGD","IE00BLSP4452.SGD","LU1244550221.USD","BK4559","LU0320765646.SGD","IE00BJT1NW94.SGD","LU0069063385.USD","LU1839511570.USD","IE00B19Z3B42.SGD","IE00BN8TJ469.HKD","LU2133065610.SGD","LU0211328371.USD","LU1244550577.SGD","LU0114720955.EUR","LU1037948541.HKD","IE00BSNM7G36.USD","SG9999011175.SGD","LU0289739699.SGD","LU1551013342.USD","LU2129689514.USD","LU0861579265.USD","LU0965509101.SGD","LU2112291526.USD","LU1989771016.USD","LU0058720904.USD","LU0289739343.SGD","LU1496350502.SGD","LU2089283258.USD","LU2129689605.HKD","LU0689626769.HKD","LU0689472784.USD","LU0738911758.USD","IE0009355771.USD","LU2237443382.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170942267","title":"异动解读 | 艾伯维盘前大跌6.5%，营收增长依赖传统药物及医美业务承压拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1170942267","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170942267?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:27","pubTimestamp":1770215246,"startTime":"0","endTime":"0","summary":"艾伯维公司（ABBV）今日盘前股价大幅下跌6.50%，引发了市场广泛关注。消息面上，尽管公司预测2026年利润高于预期，但分析师指出其营收增长主要依赖传统药物Humira，而该药销售额正受到仿制药侵蚀，引发市场担忧。同时，公司高管预计2026年医美业务增长仍将面临挑战，需通过投资刺激渗透率偏低的市场。此外，公司第四季度业绩受到收购相关无形资产研发及里程碑费用的显著拖累，对每股收益造成0.71美元的负面影响。综合来看，市场对艾伯维营收结构可持续性的疑虑、部分业务增长压力以及短期业绩受一次性费用拖累，共同导致了此次股价的大幅下跌。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABBV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154893154","title":"艾伯维高管预计2026年医美业务增长仍将承压 将重点投资刺激渗透率偏低市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1154893154","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154893154?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:23","pubTimestamp":1770214996,"startTime":"0","endTime":"0","summary":"艾伯维公司高管近日表示，预计到2026年其医美业务增长仍将面临挑战。公司正集中资源通过战略性投资来激活当前渗透率严重不足的市场。\n该高管指出，尽管面临短期增长压力，但医美市场仍存在巨大发展空间。公司将持续投入资金用于市场培育，通过创新营销策略和渠道拓展来挖掘潜在需求。\n目前全球医美市场的渗透水平仍处于低位，这既是挑战也是机遇。艾伯维将把投资重点放在提升市场认知度和可及性上，以期在未来实现业务突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089284900.SGD","LU0310799852.SGD","LU0820561909.HKD","LU0795875086.SGD","LU1074936037.SGD","LU0943347566.SGD","LU1585245621.USD","LU0310800379.SGD","IE00BSNM7G36.USD","LU1037948541.HKD","SG9999015945.SGD","LU0203345920.USD","LU1093756325.SGD","IE0002270589.USD","LU2023251221.USD","LU0432979614.USD","LU0211327993.USD","LU2129689431.USD","LU2129689514.USD","LU0320765646.SGD","BK4550","LU0820561818.USD","LU0128525929.USD","LU2347655156.SGD","LU1989771016.USD","IE00BLSP4452.SGD","LU0058720904.USD","LU1244550221.USD","LU1093756168.USD","LU0211328371.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU2237443895.HKD","LU2089283258.USD","LU1057294990.SGD","LU1267930490.SGD","LU1496350171.SGD","LU1989772840.SGD","LU0965509010.AUD","LU1551013342.USD","SG9999003800.SGD","LU0965509283.SGD","LU1430594728.SGD","LU0057025933.USD","LU2112291526.USD","IE00BJJMRZ35.SGD","BK4588","LU1934455277.USD","LU0882574055.USD","LU1732799900.SGD","BK4139","IE00BN8TJ469.HKD","SG9999015986.USD","LU1934455194.USD","LU1983299246.USD","LU1003077747.HKD","LU0708994859.HKD","LU1718418525.SGD","BK4559","LU0098860793.USD","LU0122379950.USD","BK4581","LU0203347892.USD","LU1037948897.HKD","LU0985320562.USD","LU0949170772.SGD","IE0004445239.USD","LU0511384066.AUD","LU0965509101.SGD","LU0289961442.SGD","LU0069063385.USD","LU1291159041.SGD","LU0795875169.SGD","LU0738911758.USD","LU2237443382.USD","BK4566","LU0289739343.SGD","IE00BGHQF631.EUR","LU0124676726.USD","LU1934455863.HKD","LU1989772923.USD","LU1244550494.USD","LU0256863902.USD","IE00B19Z3B42.SGD","LU1551013425.SGD","LU2237443549.SGD","LU0289739699.SGD","BK4585","IE00B3PB1722.GBP","LU0912757837.SGD","LU2237443978.SGD","LU0170899867.USD","LU0417517546.SGD","IE00B19Z3581.USD","LU0029864427.USD","LU0158827948.USD","LU0234570918.USD","IE0009355771.USD","LU0545039389.USD","LU2237443465.HKD","ABBV","LU0198837287.USD","LU0861579265.USD","LU2089984988.USD","IE00BBT3K403.USD","LU0472753341.HKD","LU2237443622.USD","LU1061106388.HKD","LU2087621335.USD","LU1732800096.USD","IE00B4R5TH58.HKD","LU1162221912.USD","IE00BVYPNW00.USD","LU2133065610.SGD","LU2129689605.HKD","LU0256863811.USD","IE00BVYPNV92.GBP","LU0114720955.EUR","LU0553294199.USD","IE00BJT1NW94.SGD","LU1929549753.HKD","SG9999015952.SGD","IE0002141913.USD","LU0661504455.SGD","SG9999015978.USD","LU1244550577.SGD","IE00BDGV0183.EUR","LU2468319806.SGD","LU1023059063.AUD","LU1839511570.USD","BK4533","LU0965508806.USD","LU0689472784.USD","BK4534","SG9999001440.SGD","LU0234572021.USD","IE00BLSP4239.USD","LU0689626769.HKD","LU1267930573.SGD","IE00B42XCP33.USD","LU1496350502.SGD","LU0456855351.SGD","SG9999011175.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608362477","title":"医美业务复苏！艾伯维Q4财报超预期，同步上调全年利润指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2608362477","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608362477?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:33","pubTimestamp":1770212037,"startTime":"0","endTime":"0","summary":"由于为提振低迷医美业务所做的一系列举措开始见效，艾伯维周三公布了超预期的第四季度业绩，同时上调了2026年盈利指引。","market":"hk","thumbnail":"https://static.tigerbbs.com/6a8642475395bb363eacb86148917e7b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6a8642475395bb363eacb86148917e7b"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401765.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"医美业务复苏！艾伯维Q4财报超预期，同步上调全年利润指引","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["ABBV"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbvie.com","stockEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.107},{"period":"3month","weight":-0.0893},{"period":"6month","weight":-0.1072},{"period":"1year","weight":0.0178},{"period":"ytd","weight":-0.086}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"艾伯维公司注册成立于2012年4月10日，是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法，来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域，包括类风湿性关节炎，牛皮癣和克罗恩病，银屑病和克罗恩病;低睾酮，HIV，子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。","yearOnYearQuotes":[{"month":1,"riseRate":0.357143,"avgChangeRate":-0.019222},{"month":2,"riseRate":0.857143,"avgChangeRate":0.039081},{"month":3,"riseRate":0.714286,"avgChangeRate":0.001102},{"month":4,"riseRate":0.571429,"avgChangeRate":0.005722},{"month":5,"riseRate":0.615385,"avgChangeRate":0.002163},{"month":6,"riseRate":0.461538,"avgChangeRate":0.008788},{"month":7,"riseRate":0.538462,"avgChangeRate":0.01232},{"month":8,"riseRate":0.538462,"avgChangeRate":0.007409},{"month":9,"riseRate":0.538462,"avgChangeRate":0.014941},{"month":10,"riseRate":0.615385,"avgChangeRate":0.007438},{"month":11,"riseRate":0.769231,"avgChangeRate":0.063841},{"month":12,"riseRate":0.692308,"avgChangeRate":0.025718}],"exchange":"NYSE","name":"艾伯维公司","nameEN":"AbbVie"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾伯维公司,ABBV,艾伯维公司股票,艾伯维公司股票老虎,艾伯维公司股票老虎国际,艾伯维公司行情,艾伯维公司股票行情,艾伯维公司股价,艾伯维公司股市,艾伯维公司股票价格,艾伯维公司股票交易,艾伯维公司股票购买,艾伯维公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}